Publications

The material below is provided to support scientific exchange. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: A plain language summary

Publication Details

Future Cardiology

May 2025

Access Here

Author(s)

Marianna Fontana¹, Julian D Gillmore¹, Ronald M Witteles², Ben Laryea³, Marc Dworkin⁴, Ann Payne⁵, Fran Kochman⁶, Satish Eraly⁶, Mathew S Maurer⁷

Affiliations

¹National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, UK; ²Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA; ³Patient author, London, UK; ⁴Patient author, Morris Plains, NJ, USA; ⁵Amyloidosis Research Consortium, Newton, MA, USA; ⁶Alnylam Pharmaceuticals, Cambridge, MA, USA; ⁷Columbia University Irving Medical Center, New York, NY, USA